Faron Announces Topline MATINS Biomarker Analysis
Faron Pharmaceuticals Ltd. (“Faron”) Topline Biomarker Analysis Shows Bexmarilimab Ignites Immune Response in Patient Population That Has Not Traditionally Benefited from Current Immunotherapy Treatments · Patients with low baseline levels of inflammatory cytokines in blood achieved significantly higher clinical benefit following treatment with bexmarilimab monotherapy · Low inflammatory biomarker profile is likely to predict bexmarilimab monotherapy clinical benefit · Ignition of immune response, as indicated by increased levels of inflammatory cytokines following